Publication
Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.
Kenneth J C Lim, Shaji Kumar, Ricardo Parrondo, Saurabh Chhabra, Melinda Tan, Katharine Dooley, Andre De Menezes Silva Corraes, Morie Gertz, Lisa Hwa, Haily Stephens, Prashant Kapoor, Taxiarchis Kourelis, Rahma Warsame, Joselle Cook, Moritz Binder, Nadine Abdallah, P Leif Bergsagel, Udit Yadav, J Erin Wiedmeier-Nutor, Susan Geyer, S Vincent Rajkumar, Sikander Ailawadhi, Rafael Fonseca, Yi Lin, Saurabh Zanwar
- Source
- PubMed
- Retrieved
- Sep 13, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260913-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Ciltacabtagene autoleucel (cilta-cel) has demonstrated excellent efficacy and long-term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available